Inhibrx Biosciences, Inc. (INBX) — Cash Flow-to-Debt Ratio
Inhibrx Biosciences, Inc. (INBX) has a Cash Flow-to-Debt Ratio of -0.22x as of December 2025, meaning its operating cash flow of $-30.12 Million could theoretically repay 0% of its total liabilities ($138.49 Million) in one year. Check how high is Inhibrx Biosciences, Inc.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Inhibrx Biosciences, Inc. Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for Inhibrx Biosciences, Inc. across 10 annual periods. Also explore INBX asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Inhibrx Biosciences, Inc. (2016–2025)
Year-by-year debt coverage analysis for Inhibrx Biosciences, Inc.. For market capitalisation and broader financial context, see Inhibrx Biosciences, Inc. (INBX) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.94x | $-129.79 Million | $138.49 Million | ▲ +77.3% |
| 2024 | -4.12x | $-194.41 Million | $47.18 Million | ▼ -463.5% |
| 2023 | -0.73x | $-193.31 Million | $264.39 Million | ▼ -47.6% |
| 2022 | -0.50x | $-115.30 Million | $232.82 Million | ▲ +39.5% |
| 2021 | -0.82x | $-80.32 Million | $98.07 Million | ▼ -16.6% |
| 2020 | -0.70x | $-47.97 Million | $68.27 Million | ▼ -163.0% |
| 2019 | -0.27x | $-32.08 Million | $120.06 Million | ▲ +21.7% |
| 2018 | -0.34x | $-23.09 Million | $67.63 Million | ▲ +27.8% |
| 2017 | -0.47x | $-18.75 Million | $39.67 Million | ▲ +47.7% |
| 2016 | -0.90x | $-18.11 Million | $20.03 Million | — |